Medtronic Q3 FY2026: Revenue $9.02B (+6% organic), non-GAAP EPS $1.36 beats guidance; reiterates FY outlook

Medtronic plc

2026-Q3 EPS reported $2.76 revenue$26,557,000,000

GAAP diluted EPS $0.89; non-GAAP diluted EPS $1.36, three cents above Q3 guidance mid-point.
Cardiovascular portfolio revenue $3.46B (+10.6% organic); Cardiac Ablation Solutions up 80% on pulsed field ablation.
Diabetes revenue $796M (+8.3% organic); Neuroscience $2.56B (+2.5% organic); Medical Surgical $2.17B (+2.7% organic).
Reiterates FY26 organic revenue growth ~5.5% and non-GAAP EPS guidance $5.62-$5.66, including ~$185M tariff impact.
Secured FDA clearances for Hugo robotic-assisted surgery and Stealth AXiS; CE Mark for Sphere-360; completed CathWorks and Anteris acquisitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.